Biotechnology

Macrogenics

Macrogenics released FY2026 Q1 earnings on May 13 (EST), actual revenue USD 20.78 M (forecast USD 15.24 M), actual EPS USD -0.5799 (forecast USD -0.548)

Macrogenics released FY2025 Q4 earnings on March 9 (EST), actual revenue USD 41.23 M (forecast USD 27.81 M), actual EPS USD -0.2236 (forecast USD -0.2896)

Macrogenics released FY2025 annual earnings on March 9 (EST), actual revenue USD 149.5 M (forecast USD 136.12 M), actual EPS USD -1.1815 (forecast USD -1.2082)

MacroGenics Reports Q3 Revenue Decline, Plans to Advance Clinical Candidates and Seek New Capital

Macrogenics released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 72.84 M (forecast USD 28.72 M), actual EPS USD 0.266 (forecast USD -0.4015)

Macrogenics released FY2025 9 Months Earnings on November 12 (EST), actual revenue USD 108.27 M, actual EPS USD -0.9598

Macrogenics released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 22.24 M (forecast USD 28.06 M), actual EPS USD -0.5741 (forecast USD -0.4702)

Macrogenics released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 35.43 M, actual EPS USD -1.2257

MacroGenics Obtains $70 Million Royalty Purchase Agreement Advance Payment

MacroGenics Announces Updates on Company Members

B. Riley Maintains Neutral Rating on Macrogenics and Adjusts Target Price Downwards

Dimensional Fund Advisors Reduces MacroGenics Stock Holdings

Barclays Downgrades Macrogenics Price Target to $3.00

Macrogenics released FY2025 Q1 earnings on May 13 After-Market EST, actual revenue USD 13.19 M (forecast USD 9.593 M), actual EPS USD -0.6517 (forecast USD -0.7216)

Biopharmaceutical Company Macrogenics to Release Quarterly Earnings Report

MacroGenics Inc reports Q1 EPS loss of 78 cents, 32.3% revenue decline

MacroGenics plans to release Q1 2025 earnings report

Macrogenics to Release FY2025 Q1 Earnings on May 13 After-Market EST, Forecast Revenue USD 9.593 M, EPS USD -0.7216

MacroGenics to Attend an Investor Meeting

HC Wainwright & Co. Adjusts Rating and Target Price for Macrogenics

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

BiomX

Vida Global

MetaVia

MicroAlgo

Tradr 2X Long XNDU Daily ETF

MGNX

IBBQ

ARKG

LABU

MacroGenics, Inc. will participate in the Stifel 2026 Virtual Targeted Oncology Forum on May 20, 2026, at 10:30 a.m. ET. President and CEO Eric Risser will engage in a fireside chat to discuss innovative cancer treatments and the company's strategies in oncology. MacroGenics is listed on Nasdaq as MGNX and focuses on developing antibody-based therapies for cancer.

Unusual Whales

SPDR S&P Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Stifel Financial

Nasdaq

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum

Barclays analyst Etzer Darout has reaffirmed a Buy rating on MacroGenics (MGNX) with a price target of $6.00. The analyst focuses on the Healthcare sector and has an average return of 26.4% with a 56.04% success rate on stock recommendations. The current consensus on MacroGenics is a Moderate Buy, with an average price target of $6.33.

Tip Ranks

VG Health

iShares US Pharma

Health Care Select Sector SPDR

Barclays

Incyte

Legend Biotech

Oruka Therapeutics

Barclays Reaffirms Their Buy Rating on MacroGenics (MGNX)

CSCO

Cisco night trading rose 20.30%; Macrogenics night trading rose 7.25%; Leslies night trading rose 25.87%; Innoviz Tech night trading rose 13.48%; Stubhub - CL night trading rose 12.50%

Price Alert

Cisco

Leslies

Innoviz Tech

Stubhub - CL

U.S. stock night trading opens with fluctuations: Cisco rises 20.30% in night trading; Macrogenics rises 7.25% in night trading

Earnings Watch

Macrogenics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 20.78 M

MacroGenics shares are trading higher after the company announced it will sell GMP Manufacturing to Bora Pharmaceuticals.

benzinga_article

MacroGenics has agreed to sell its Maryland biologics manufacturing operations to Bora Pharmaceuticals for $122.5 million, with an additional $5 million tied to future milestones. The deal, expected to close in Q3 2026, will transfer around 140 employees and an FDA-approved facility to Bora. MacroGenics will retain its research operations and gain non-dilutive capital to support its oncology pipeline. Analysts rate MGNX stock as a Buy with a $6.00 price target, though concerns about financial performance persist.

iShares Global Healthcare

MacroGenics Sells Maryland Biologics Manufacturing to Bora

USBC

In Tuesday's pre-market session, PACS Group saw a significant gain of 17.6%, reaching $37.5, with a market cap of $5.0 billion. Other notable gainers included Akari Therapeutics (+16.31%), Macrogenics (+16.27%), and USBC (+12.69%). Conversely, WORK Medical Tech experienced a sharp decline of 45.7%, followed by CEL-SCI (-26.25%) and Pomdoctor (-22.69%). Overall, the session highlighted substantial movements in health care stocks, influenced by recent earnings reports.

WORK Medical Tech

CEL-SCI

PACS

Pomdoctor

Akari Therap

SPDR S&P Health

iShares US Healthcare Providers

iShares US Medical Devices

SPDR S&P Health Equip

Phio Pharmaceuticals

Dyadic

China Pharma

Organigram

Ensysce Biosciences

Ensysce Biosciences - CW22

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

MacroGenics, Inc. has entered into an agreement to sell its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million. The deal includes the transfer of a manufacturing site and associated personnel, with the transaction expected to close in Q3 2026. This move aligns with MacroGenics' strategy to focus on its innovative pipeline and provide non-dilutive capital. Bora aims to enhance its North American biologics operations through this acquisition, which will also see approximately 140 MacroGenics employees hired by Bora.

StockTitan

Moelis

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals | MGNX Stock News

Macrogenics(MGNX.US)